Dersimelagon (MT-7117)

Erythropoietic protoporphyria or X-linked protoporphyria

Manufacturer: LEO Pharma
Regulatory submission: NDA submitted June 2026
Launch: Potential launch in 2027
Last updated: September 21, 2026

Section

Product information and disease description Product description

Product information

53 evidence topics · 32 sources

Generic, brand name and therapeutic class of product6 evidence topics · 7 sources
Dosage forms and strengths3 evidence topics · 4 sources
Average sales price and wholesale acquisition cost1 evidence topic · 1 source
American hospital formulary service (AHFS), or other drug classification1 evidence topic · 1 source
Indication4 evidence topics · 5 sources
Pharmacology9 evidence topics · 7 sources
Contraindications/Warnings/Precautions/Adverse effects4 evidence topics · 5 sources
Special populations4 evidence topics · 4 sources
Drug/Drug, drug/disease interactions3 evidence topics · 3 sources
Dosing and administration6 evidence topics · 8 sources
Co-prescribed/Concomitant therapies3 evidence topics · 2 sources
Product comparison9 evidence topics · 11 sources

Access and distribution

No evidence found.

Effect of Dersimelagon on quality measures

No evidence found.